Viatris
Search results
Mylan is now part of Viatris, a new company that aims to provide quality medicines for patients worldwide. Learn more about Viatris' vision, values and products on their website.
- Events & Presentations
The Investor Relations website contains information about...
- Investors
Mylan is now part of Viatris, a new global healthcare...
- News Archive
Mylan and Pfizer Receive Clearance from the U.S. Federal...
- Events & Presentations
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be. Learn about our story, explore our products and browse career opportunities.
Nov 12, 2019 · HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs).
Viatris is a global healthcare company that was formed by the combination of Mylan and Upjohn in 2020. Learn about the history, vision and mission of both Mylan and Upjohn, and how they evolved to become Viatris.
On November 16, 2020, Upjohn merged with Mylan in a Reverse Morris Trust transaction and changed its name to Viatris. At that time, Michael Goettler became chief executive officer. Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS.
We are a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both, to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale.
